Novel scaffolds are of uttermost importance for the discovery of functional material. Three different heterocyclic scaffolds easily accessible from isocyanoacetaldehyde dimethylacetal 1 by multicomponent reaction (MCR) are described. They can be efficiently synthesized by a Ugi tetrazole multicomponent reaction of 1. We discuss the synthesis, 3D structures, and other physicochemical properties.
Novel scaffolds are of uttermost importance for the discovery of functional material. Three different heterocyclic scaffolds easily accessible from isocyanoacetaldehydedimethylacetal 1 by multicomponent reaction (MCR) are described. They can be efficiently synthesized by a Ugitetrazole multicomponent reaction of 1. We discuss the synthesis, 3D structures, and other physicochemical properties.
Novel scaffolds form the basis
for success in the discovery of bioactive compounds, which eventually
can be developed to drugs for the treatment of unmet medical needs.
A decade ago the NIH started an initiative (Molecular Libraries Program
(MLP)) to assemble a large chemical library to be screened by academic
institutions to yield, after optimization, in vitro tool compounds
(molecular probes) for novel targets showing activity and selectivity
in cell based systems.[1] These tool compounds
can be accessed by interested researchers and are of importance to
elucidate the interplay of novel targets in biology and disease.[2] The European Lead Factory (ELF), a public private
partnership, is a complementary European initiative with similar targets
aiming for a library of 500 000 novel compounds by 2017.[3] The availability of molecular probes (small molecule
or antibody) has been recently and impressively demonstrated to be
a key determinant of progress in basic biology and disease areas.[4]From a practical point of view the synthesis
of medium sized high
quality libraries is demanding. The use of a “universal building
block” in the synthesis of different scaffolds has great advantages
in the parallel synthesis of larger libraries. For example, unprotected
α-amino acids have been used recently in different multicomponent
reaction chemistry to stereoselectively afford a diversity of novel
cyclic and acyclic scaffolds, including amido-aminophosphonates,[5] boneratamide analogues,[6] iminodicarboxamides,[7] iminobenzazocineacetamide,[8] boropeptides,[9] thiolactone and
thiomorpholino, diketopiperazines,[10] seleno amino acid,[11] imidazol,[12] or indol derivatives.[13]Isocyanide 1 as its diethyl
acetal was first described
by Hardtke in 1966 and now robust large scale syntheses exist.[14] Competitive analysis shows few applications
of the building block 1 in heterocycle synthesis toward
1-aryl-2-arylthio-1H-imidazoles and imidazo[1,5-a]imidazoles (Scheme 1).[15] Other scaffolds reported include thiazoles and
chiral imidazoles both by a thio Ugi reaction.[16] Here we describe the easy synthesis of different scaffolds 2–4 using the same easily accessible building
block 1, while not compromising diversity aspects.
Scheme 1
Previously Elaborated Heterocyclic Scaffold Using Isocyanide 1 and Our Work toward Three Novel Heterocycles
We envisioned that tetrazole annulated piperazine
scaffold 2 could be accessed from the Ugi-tetrazole reaction
using
isocyanide building block 1, primary amines 5, aldehydes or ketones 6, and TMSN37 (Scheme 2) and subsequent cyclization/elimination
via the secondary amine. In the optimization campaign the reaction
is performed in methanol at ambient temperature. The Ugi adduct 8 was further treated with neat acetic acid at 80 °C
but did not yield the cyclized product 2. Similar results
were obtained with trifluoroacetic acid, methanesulfonic acid with
and without solvents such as CH2Cl2, CH3CN, and toluene at 50–80 °C. However, the Ugi-adduct 8 stirred with neat methanesulfonic acid for 18 h at ambient
temperature afforded scaffold 2 in good yields.
Scheme 2
Designed
Synthetic Pathway to Tetrazolo Piperazine Scaffold 2
In general, the Ugi reaction
works well with aromatic and aliphatic
aldehydes and ketones. In the post-Ugi reaction we observed that aliphatic
aldehyde, ketones, and electron-deficient benzaldehydes could be used
to give the product 2 in good yield. Electron-rich benzaldehydes
also worked, however giving the desired product in low yields (2c). Typical examples are shown in Table 1.
Table 1
Typical Structures and Yields of Scaffold 2
Isolated yields for Ugi reaction
and cyclization.
Isolated yields for Ugi reaction
and cyclization.When more
electron-rich benzaldehydes
(10) are used
the intermediate Ugitetrazole product undergoes a different cyclization
pathway and can be reacted further to yield tetrazolo-phenyl-azepine
scaffold 3 involving a o-phenol addition
and elimination (Scheme 3). 3,5-Dimethoxy benzaldehyde
gives better yields then 3,4,5-trimethoxy and 3,4-dimethoxy benzaldehydes.
Generally both primary and secondary amines used gave moderate to
good yields while the use of anilines caused the yield of our desired
product to drop (3h). Typical examples and yields are
shown in Table 2.
Scheme 3
Designed Synthetic
Pathway to Benzotetrazolo Azepinamine Scaffold 3
Table 2
Typical Structures
and Yields of Scaffold 3
Isolated yields
for Ugi reaction
and cyclization.
Isolated yields
for Ugi reaction
and cyclization.The use
of electron-rich 2-(heteroaromatic)ethylamines 13 allows for access to polycyclic scaffold 4. The intermediate Ugitetrazole 14 yet undergoes a
different reaction pathway and can be further reacted in a Pictet–Spengler
transformation according to Scheme 4. Various
aldehydes and ketones were tested, and all generated the product in
satisfactory yields (Table 3). In most cases
the products were obtained as a single major diastereomer; however,
in the case of tryptophan methyl ester the Ugi products were obtained
as a diastereomeric mixture of 14i (3:2) and 14j (2:1) and corresponding cyclized products 4i (9:1)
and 4j (2:1).
Scheme 4
Designed Synthetic Pathway to Pyridotetrazolo
Piperazine Scaffold 4
Table 3
Typical Structures and Yields of Scaffold 4
Isolated yields for Ugi reaction
and cyclization.
Dr ratio
was determined by SFC-MS
and 1H NMR.
Isolated yields for Ugi reaction
and cyclization.Dr ratio
was determined by SFC-MS
and 1H NMR.Next
we investigated the structure of exemplary compounds of each
scaffold in the solid state (Figure 1). We
could grow three crystals of 2e, 3c, and 4f suitable for single crystal structure determination confirming
the scaffold design and showing intermolecular interactions.
Figure 1
3D structure
of examples of scaffolds 2–4 in the
solid state.
3D structure
of examples of scaffolds 2–4 in the
solid state.With the general synthesis
of these scaffolds we set forth to create
a virtual library of all three tetrazole reactions to analyze some
of their general physicochemical features. We randomly generated 1000
examples of each scaffold. To visualize the distribution in a 3D chemical
space unbiased molecular descriptors were analyzed by principal component
analysis (PCA) (Figure 2B and Supplemental Figure 2). Interestingly, even though these scaffolds
are all derived from the same first Ugitetrazole multicomponent reaction
they possess very different characteristics in terms of their chemical
space due to their connectivity, substitution pattern, and ring sizes.
To visualize this difference, 3D generation and alignment of the tetrazole
ring on all three scaffolds was done (Figure 2A). As can be seen, due to the different rings that stem from the
tetrazole base the three scaffolds each occupy a different space.
Figure 2
(a) Overlay
of energy-minimized conformers of the backbones of
the three scaffolds described in this paper (green = scaffold 2, blue
= scaffold 3, orange = scaffold 4). (b) 2D principal component analysis
of 1000 randomly generated compounds of each of the three scaffolds
described in this paper (green = scaffold 2, blue = scaffold 3, red
= scaffold 4).
(a) Overlay
of energy-minimized conformers of the backbones of
the three scaffolds described in this paper (green = scaffold 2, blue
= scaffold 3, orange = scaffold 4). (b) 2D principal component analysis
of 1000 randomly generated compounds of each of the three scaffolds
described in this paper (green = scaffold 2, blue = scaffold 3, red
= scaffold 4).To study this concept
further we performed the principal moment
of inertia (PMI)[17] analysis to compare
the shape distribution of our virtual library of small molecules to
that of 1000 randomly selected compounds from the ZINC library[18] (Supplemental Figure 1). As expected, based on the previous data, the three scaffolds occupy
different 3D spaces and tend to be more 3D in nature to compounds
from the ZINC database. The three-dimensionality of lead compounds
recently emerged as an important concept to provide “drug-like”
properties, e.g. reduced promiscuity or water solubility.[19] Interestingly, scaffold 2 occupies
a wider array of space compared to scaffolds 3 and 4 which cluster closer together. This is most likely due to
the substitution pattern on scaffold 2, using two widely
variable starting materials.Work is ongoing to leverage the
new chemical space to discover
biologically active compounds and will be reported in due course.
Authors: Andrea F G Gargano; Stefanie Buchinger; Michal Kohout; Wolfgang Lindner; Michael Lämmerhofer Journal: J Org Chem Date: 2013-10-08 Impact factor: 4.354
Authors: Aled M Edwards; Ruth Isserlin; Gary D Bader; Stephen V Frye; Timothy M Willson; Frank H Yu Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Jeremy M Travins; Shunqi Yan; Fang Zhao; Stefan Gross; Lenny Dang; Katharine E Yen; Hua Yang; Kimberly S Straley; Shengfang Jin; Kaiko Kunii; Valeria R Fantin; Shunan Zhang; Qiongqun Pan; Derek Shi; Scott A Biller; Shinsan M Su Journal: ACS Med Chem Lett Date: 2012-09-17 Impact factor: 4.345
Authors: Joseph A Maddry; Subramaniam Ananthan; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Clinton Maddox; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Melinda I Sosa; E Lucile White; Wei Zhang Journal: Tuberculosis (Edinb) Date: 2009-09-26 Impact factor: 3.131